Chong Kun Dang Holdings Corp. (001630.KS)
KRW 50100.0
(-0.6%)
KRW 50100.0
(-0.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 47 Billion KRW | 307.41% |
| 2022 | -22.66 Billion KRW | -187.76% |
| 2021 | 25.82 Billion KRW | -77.27% |
| 2020 | 113.62 Billion KRW | 43.23% |
| 2019 | 79.32 Billion KRW | 188.92% |
| 2018 | 27.45 Billion KRW | -42.81% |
| 2017 | 48 Billion KRW | 63.12% |
| 2016 | 29.43 Billion KRW | 93.53% |
| 2015 | 15.2 Billion KRW | 60.75% |
| 2014 | 9.46 Billion KRW | -97.72% |
| 2013 | 415.73 Billion KRW | 1198.88% |
| 2012 | 32 Billion KRW | -40.2% |
| 2011 | 53.52 Billion KRW | 20.98% |
| 2010 | 44.24 Billion KRW | 72.23% |
| 2009 | 25.68 Billion KRW | 18.69% |
| 2008 | 21.64 Billion KRW | 8.98% |
| 2007 | 19.86 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 8.79 Billion KRW | -31.04% |
| 2024 Q2 | 15.3 Billion KRW | 73.97% |
| 2023 Q3 | 11.26 Billion KRW | 4.48% |
| 2023 Q2 | 10.77 Billion KRW | -11.72% |
| 2023 Q1 | 12.2 Billion KRW | 417.1% |
| 2023 Q4 | 12.75 Billion KRW | 13.31% |
| 2023 FY | 47 Billion KRW | 307.41% |
| 2022 Q4 | -3.85 Billion KRW | 62.91% |
| 2022 Q1 | 1.95 Billion KRW | 633.93% |
| 2022 FY | -22.66 Billion KRW | -187.76% |
| 2022 Q2 | -10.39 Billion KRW | -630.92% |
| 2022 Q3 | -10.38 Billion KRW | 0.1% |
| 2021 Q2 | 6.73 Billion KRW | 6.22% |
| 2021 FY | 25.82 Billion KRW | -77.27% |
| 2021 Q4 | 266.65 Million KRW | -89.94% |
| 2021 Q1 | 6.34 Billion KRW | -79.22% |
| 2021 Q3 | 2.64 Billion KRW | -60.66% |
| 2020 Q4 | 30.52 Billion KRW | 74.03% |
| 2020 Q2 | 17.12 Billion KRW | 26.92% |
| 2020 Q1 | 13.49 Billion KRW | 58.04% |
| 2020 FY | 113.62 Billion KRW | 43.23% |
| 2020 Q3 | 17.53 Billion KRW | 2.41% |
| 2019 Q4 | 8.53 Billion KRW | -31.36% |
| 2019 FY | 79.32 Billion KRW | 188.92% |
| 2019 Q1 | 20.23 Billion KRW | 348.12% |
| 2019 Q2 | 3.81 Billion KRW | -81.12% |
| 2019 Q3 | 12.43 Billion KRW | 225.68% |
| 2018 Q1 | 14.96 Billion KRW | -9.41% |
| 2018 Q2 | 2.5 Billion KRW | -83.24% |
| 2018 Q4 | 4.51 Billion KRW | -17.43% |
| 2018 Q3 | 5.46 Billion KRW | 117.98% |
| 2018 FY | 27.45 Billion KRW | -42.81% |
| 2017 Q4 | 16.51 Billion KRW | 92.35% |
| 2017 Q2 | 5.58 Billion KRW | -67.75% |
| 2017 Q1 | 17.31 Billion KRW | 225.74% |
| 2017 FY | 48 Billion KRW | 63.12% |
| 2017 Q3 | 8.58 Billion KRW | 53.8% |
| 2016 Q3 | 14.12 Billion KRW | 200.94% |
| 2016 Q1 | 5.29 Billion KRW | 63.16% |
| 2016 Q4 | 5.31 Billion KRW | -62.37% |
| 2016 FY | 29.43 Billion KRW | 93.53% |
| 2016 Q2 | 4.69 Billion KRW | -11.32% |
| 2015 Q1 | 35.16 Million KRW | 100.51% |
| 2015 Q4 | 3.24 Billion KRW | -20.29% |
| 2015 Q3 | 4.06 Billion KRW | -48.21% |
| 2015 Q2 | 7.85 Billion KRW | 22247.14% |
| 2015 FY | 15.2 Billion KRW | 60.75% |
| 2014 Q1 | 5.26 Billion KRW | -98.59% |
| 2014 Q4 | -6.87 Billion KRW | -261.99% |
| 2014 FY | 9.46 Billion KRW | -97.72% |
| 2014 Q3 | 4.24 Billion KRW | -37.84% |
| 2014 Q2 | 6.82 Billion KRW | 29.57% |
| 2013 Q2 | 15.64 Billion KRW | 37.21% |
| 2013 Q3 | 15.32 Billion KRW | -2.05% |
| 2013 Q4 | 373.35 Billion KRW | 2335.61% |
| 2013 FY | 415.73 Billion KRW | 1198.88% |
| 2013 Q1 | 11.4 Billion KRW | 0.49% |
| 2012 Q1 | 7 Billion KRW | 0.0% |
| 2012 Q2 | 12.96 Billion KRW | 85.21% |
| 2012 Q3 | -620.14 Million KRW | -104.78% |
| 2012 Q4 | 11.34 Billion KRW | 1930.1% |
| 2012 FY | 32 Billion KRW | -40.2% |
| 2011 Q2 | 13.83 Billion KRW | 22.59% |
| 2011 FY | 53.52 Billion KRW | 20.98% |
| 2011 Q1 | 11.28 Billion KRW | 0.0% |
| 2011 Q3 | 14.41 Billion KRW | 4.22% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 11 Billion KRW | -13.84% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 44.24 Billion KRW | 72.23% |
| 2010 Q2 | 12.77 Billion KRW | 56.82% |
| 2010 Q1 | 8.14 Billion KRW | 0.0% |
| 2009 Q3 | 10.02 Billion KRW | 56.14% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q2 | 6.42 Billion KRW | 0.41% |
| 2009 Q1 | 6.39 Billion KRW | 0.0% |
| 2009 FY | 25.68 Billion KRW | 18.69% |
| 2008 Q1 | 5.66 Billion KRW | 0.0% |
| 2008 Q3 | 4.87 Billion KRW | -1.39% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 4.94 Billion KRW | -12.68% |
| 2008 FY | 21.64 Billion KRW | 8.98% |
| 2007 Q1 | 7.99 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q3 | 4.49 Billion KRW | -12.17% |
| 2007 Q2 | 5.11 Billion KRW | -35.97% |
| 2007 FY | 19.86 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 754.618% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 18.938% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 178.889% |
| HANDOK Inc. | -28.79 Billion KRW | 263.235% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 658.603% |
| Yuhan Corporation | 93.5 Billion KRW | 49.73% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -322.635% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 289.454% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 67.854% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -1239.776% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1975.487% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 2366.612% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 1138.877% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -110.487% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 754.618% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 324.477% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -1211.822% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 139.746% |
| JW Holdings Corporation | 19.02 Billion KRW | -147.066% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 159.557% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 77.881% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -27.026% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 182.001% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -667.875% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -2725.751% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -839.258% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 754.618% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -27.166% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 57.842% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -27.026% |
| Yuhan Corporation | 93.5 Billion KRW | 49.73% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 389.281% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 1312.926% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -668.193% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -27.026% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -148.641% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 2.599% |
| CKD Bio Corp. | -24.19 Billion KRW | 294.306% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -96.545% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -71.321% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -57.879% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 182.001% |
| Boryung Corporation | 40.2 Billion KRW | -16.926% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 250.041% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1975.487% |
| JW Lifescience Corporation | 28.14 Billion KRW | -67.025% |